Clinical Trials List
2018-12-25 - 2024-07-04
Phase III
Recruiting4
Terminated1
ICD-9151.0
Malignant neoplasm of cardia of stomach
-
Trial Applicant
PAREXEL INTERNATIONAL CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Yi-Chang Liu Division of General Internal Medicine
- Ta-Chih Liu Division of General Internal Medicine
- Hui-Ching Wang Division of General Internal Medicine
- Li-Tzong Chen Division of General Internal Medicine
- 蔡郁棻 Division of General Internal Medicine
- Fang-Jung Yu Yu Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chieh-Lin Teng Division of General Internal Medicine
- 鄭紹彬 Division of General Internal Medicine
- 林欣 Division of General Internal Medicine
- YU-HSUAN SHIH Division of General Internal Medicine
- SHAO-CIAO LUO Division of General Internal Medicine
- 滕傑林 Division of General Internal Medicine
- CHENG-HSIEN LIN Division of General Internal Medicine
- Tsung -Chih Chen Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chih-Ming Chou Division of General Internal Medicine
- Chang-Yun Lu Division of General Internal Medicine
- Mao-Chih Hsieh Division of General Internal Medicine
- Wei-Wen Chang Division of General Internal Medicine
- 謝茂 Division of General Internal Medicine
- 方嘉郎 Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Audit
None
Co-Principal Investigator
- 林建良 Division of General Internal Medicine
- 陳昭勳 Division of General Internal Medicine
- Shang-Wen Chen Division of General Internal Medicine
- 曹朝榮 Division of General Internal Medicine
- 陳彥勳 Division of General Internal Medicine
- 蕭聖諺 Division of General Internal Medicine
- 黃文聰 Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
Audit
CRO
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
11 participants
-
Global
507 participants
